West Pharmaceutical Services (WST) EV to CFO (2009 - 2026)

West Pharmaceutical Services has disclosed EV to CFO across 18 years of filings, most recently posting 200.3 for Q2 2026.

• In Q2 2026, EV to CFO rose 133.04% year-over-year to 200.3; the TTM figure through Jun 2026 stood at 37.51 (up 66.74% YoY), while the FY2025 annual figure was 25.2, down 29.03% from the prior year.
• EV to CFO came in at 200.3 for Q2 2026 at West Pharmaceutical Services, up from 191.87 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 239.3 in Q1 2024 to a low of 71.69 in Q4 2022.
• Average EV to CFO over 5 years is 136.1, with a median of 121.57 recorded in 2024.
• Year-over-year, EV to CFO tumbled 66.13% in 2022 and jumped 133.04% in 2026.
• Over 5 years, EV to CFO stood at 71.69 in 2022, then soared by 46.01% to 104.67 in 2023, then advanced by 16.58% to 122.03 in 2024, then slumped by 37.93% to 75.74 in 2025, then surged by 164.46% to 200.3 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 200.3 in Q2 2026, 191.87 in Q1 2026, and 75.74 in Q4 2025.